Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274744 | 1.00 | OPRM1 (0.71) | OPRM1OPRD1 | |
| SCHEMBL3273677 | 0.89 | OPRM1 (0.73) | OPRM1OPRD1 | |
| SCHEMBL20942745 | 0.89 | OPRM1 (0.73) | OPRM1OPRD1 | |
| SCHEMBL1764844 | 0.89 | OPRM1 (0.73) | OPRM1OPRD1 | |
| SCHEMBL1764847 | 0.89 | OPRM1 (0.73) | OPRM1OPRD1 | |
| SCHEMBL3273675 | 0.89 | OPRM1 (0.73) | OPRM1OPRD1 | |
| SCHEMBL1764391 | 0.86 | OPRM1 (0.77) | OPRM1OPRD1 | |
| SCHEMBL1845078 | 0.86 | OPRM1 (0.77) | OPRM1OPRD1 | |
| SCHEMBL1764392 | 0.86 | OPRM1 (0.77) | OPRM1OPRD1 | |
| SCHEMBL1845075 | 0.86 | OPRM1 (0.77) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211894-B2 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7691878-B2 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885 |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.